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Atypical 
antipsychotics 
are an effective 
short-term 
treatment for 
aggressive 
behavior. 
Evidence summary 
Psychotic symptoms, including aggression, in 
patients with dementia are a leading cause of 
nursing home placement and pharmacologic 
treatment. RCTs have demonstrated the ef-
fi cacy of atypical antipsychotics in aggressive 
nursing home patients. 
Risperidone signiﬁ cantly reduces aggression
An RCT comparing risperidone with pla-
cebo in 345 patients found that low-dose 
risperidone (mean 0.95 mg/d) signifi cantly 
improved aggression scores (number needed 
to treat [NNT]4; P<.001). Serious adverse 
events included injury, cerebrovascular 
events, pneumonia, and accidental overdose 
(number needed to harm [NNH]13).1 Other 
RCTs also have found risperidone to be eff ec-
tive in reducing aggressive behavior.2,3 
Olanzapine is effective and well tolerated
Researchers have also studied olanzapine, 
another atypical antipsychotic. A 6-week RCT 
of 206 elderly nursing home patients with Al-
zheimer’s disease and psychotic or behavioral 
symptoms found that low-dose olanzapine 
(5 or 10 mg/d) decreased agitation and 
aggression scores (olanzapine 5 mg: 
NNT=5; olanzapine 10 mg: NNT=6) com-
pared with placebo. Commonly report-
ed adverse eff ects included somnolence 
(5 mg: NNH=5; 10 mg: NNH=5) and gait dis-
turbance (5 mg: NNH=6; 10 mg: NNH=8).4 
An open-label follow-up study also found 
low-dose olanzapine to be well tolerated 
and eff ective in decreasing agitation and 
aggression scores.5
Weigh the beneﬁ ts against the risks
Th e US Food and Drug Administration is-
sued a public health advisory regarding in-
creased mortality risk after reviewing RCTs 
that evaluated atypical antipsychotics in 
patients with dementia.6 A meta-analysis of 
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EVIDENCE-BASED ANSWER
A  atypical antipsychotics are   effective; so are selective serotonin 
reuptake inhibitors (SSRIs), and they may be 
safer. Atypical antipsychotics are an eff ective 
short-term (6-12 weeks) treatment for aggres-
sive behavior in patients with Alzheimer’s 
disease because they consistently decrease 
aggression scores (strength of recommen-
dation [SOR]: A, multiple randomized con-
trolled trials [RCTs]). However, evidence of 
drug-related deaths in patients taking these 
drugs mandates weighing the benefi ts against 
the risks. SSRIs may be a safer, eff ective alter-
native (SOR: B, limited studies). 
Evidence for the effi  cacy of antiepilep-
tic agents is confl icting (SOR: C, inconsis-
tent patient-oriented evidence). Valproate 
is ineff ective for treating aggression (SOR: 
C, very small RCT). 
No data exist to guide long-term medi-
cation use. All available studies lasted no 
longer than 12 weeks.
Nonpharmacologic therapy should 
be the fi rst-line treatment for aggres-
sion in patients with Alzheimer’s disease. 
Consider drug therapy for patients who 
pose an imminent threat to themselves 
or others.
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SSRIs may be a 
safer, effective 
alternative to 
antipsychotics.
15 RCTs (N=5110) that studied olanzapine, 
aripiprazole, risperidone, and quetiapine 
in patients with dementia demonstrated a 
small, but increased risk of death associat-
ed with their use when compared with pla-
cebo (3.5% vs 2.3%; odds ratio=1.54; 95% 
confi dence interval [CI], 1.06-2.23; P=.02; 
NNH= 83).7 
A population-based (community and 
long-term care facilities), retrospective cohort 
study of atypical and conventional antipsy-
chotics involving 27,259 matched pairs also 
suggested an increased risk of death. Th irty 
days after beginning an atypical antipsy-
chotic medication, increased mortality was 
noted when compared with no antipsychotic 
use in both the community cohort (adjusted 
hazard ratio [AHR]=1.31 [95% CI, 1.02-1.70]; 
NNH=500) and the long-term care cohort 
(AHR=1.55 [95% CI, 1.15-2.07]; absolute risk 
diff erence=1.2 percentage points; NNH=83). 
Conventional antipsychotics were associ-
ated with higher rates of death than atypi-
cal antipsychotics (absolute risk diff erence=
2.6 percentage points in the community 
group [NNH=38] and 2.2 percentage points 
in the long-term care groups [NNH=45]).8 
SSRIs may be an alternative
An RCT comparing citalopram and risperi-
done over 12 weeks in 103 patients with de-
mentia demonstrated similar effi  cacy for the 
2 drugs in treating agitation. Patients receiv-
ing citalopram experienced fewer adverse ef-
fects than those receiving risperidone.9 Th e 
study suggests that SSRIs may be an alterna-
tive to atypical antipsychotics. 
Carbamazepine helps, valproate doesn’t
Evidence regarding the use of antiepileptic 
medications is confl icting. One RCT of 51 pa-
tients found carbamazepine 300 mg daily to be 
effi  cacious for short-term control of agitation 
with good safety and tolerability. Six weeks 
after beginning the study, Overt Aggression 
Scale scores decreased 6.7 points for carbam-
azepine compared with 1.9 points for placebo 
(P=.008). Adverse eff ects, including ataxia, 
drowsiness, postural instability, rash, weak-
ness, and disorientation, were more com-
mon in the carbamazepine group than the 
placebo group (absolute risk increase=30%; 
NNH=3).10 
When compared with placebo, 480 mg 
daily of sodium valproate for 8 weeks showed 
no diff erences in controlling aggressive be-
havior.11 In an open-label follow-up study, 
aggressive behavior improved from 10.52 
on the Social Dysfunction and Aggression 
Scale to 6.31 (P<.001), but no improvement 
was observed using the Clinical Global Im-
pression Scale for aggressive behavior. Seven 
deaths that authors couldn’t attribute to the 
drug occurred. Th ree patients experienced 
drowsiness. No other adverse events were 
noted.12
A very small, double-blind crossover 
RCT (N=14) evaluated 250 to 1500 mg so-
dium valproate daily for 6 weeks compared 
with placebo. A 2-week period separated the 
valproate and placebo regimens. Neuropsy-
chiatric Inventory agitation and aggression 
scores worsened signifi cantly with valpro-
ate (increase of 1.43 points compared with a 
decrease of 2.08 points with placebo; P=.04). 
Adverse events related to valproate included 
falls, sedation, loss of appetite, thrombocyto-
penia, and loose stools (NNH=3).13
Recommendations
Th e Expert Consensus Guideline for the 
Treatment of Agitation in Older Persons with 
Dementia14 and treatment guidelines for Al-
zheimer’s disease and other dementias from 
the American Psychiatric Association (APA)15 
off er diff erent recommendations for fi rst-line 
treatment. 
Th e Expert Consensus Guideline rec-
ommends divalproate, risperidone, and 
conventional high-potency antipsychotics 
for patients with severe anger and physical 
aggression. Alternative treatments include 
olanzapine, carbamazepine, trazodone, and 
SSRIs.14 
Th e APA recommends antipsychotics to 
treat agitation based on available evidence. 
If treatment fails, consider anticonvulsants, 
lithium, or beta-blockers. Th e APA notes that 
although evidence for SSRIs is limited, they 
may be appropriate for agitated nonpsychot-
ic patients.15                       JFP
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No data exist 
to guide 
long-term 
medication use 
for aggressive 
behavior in 
patients with 
Alzheimer’s 
disease. 
